Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dusigitumab - AstraZeneca

Next Previous
Drug Profile

Dusigitumab - AstraZeneca

Alternative Names: MEDI-573

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor I inhibitors; Insulin-like growth factor II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Liver cancer; Solid tumours

Most Recent Events

  • 28 Jun 2019 MedImmune completes a phase Ib/II trial for Breast cancer (Combination therapy, Metastatic disease) in USA, Canada, Bahamas, United Kingdom, Belgium, France, Germany, Hungary, Poland, Spain & Israel (IV) (NCT01446159)
  • 09 Feb 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Japan (IV) due to safety and efficacy issues before February 2018 (MedImmune pipeline, February 2018)
  • 09 Feb 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) due to safety and efficacy issues before February 2018 (MedImmune pipeline, February 2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top